Pediatric SARS-CoV-2 Seroprevalence, Oregon, USA, November 1, 2020-June 30, 2022

Rebecca A. Falender; Paul G. Mitchell; Judith A. Guzman-Cottrill; Paul R. Cieslak; Melissa Sutton

doi:10.3201/eid2908.230471

Pediatric SARS-CoV-2 Seroprevalence, Oregon, USA, November 1, 2020-June 30, 2022

Rebecca A. Falender, Paul G. Mitchell, Judith A. Guzman-Cottrill, Paul R. Cieslak, Melissa Sutton

Pediatrics

Research output: Contribution to journal › Article › peer-review

Abstract

We estimated SARS-CoV-2 seroprevalence in children in Oregon, USA, at 6 time points. Seroprevalence increased linearly during November 2020-December 2021 and peaked in February 2022 at 38.8% (95% CI 32.8%-46.5%). We observed no increase in the seroprevalence trend after widespread school reopening. Seroprevalence estimates complement case-based cumulative incidence.

Original language	English (US)
Pages (from-to)	1672-1675
Number of pages	4
Journal	Emerging infectious diseases
Volume	29
Issue number	8
DOIs	https://doi.org/10.3201/eid2908.230471
State	Published - Aug 2023

ASJC Scopus subject areas

Epidemiology
Microbiology (medical)
Infectious Diseases

Access to Document

10.3201/eid2908.230471

Cite this

@article{edb6d43fe7c44fe8abe3fde8553d0d1a,

title = "Pediatric SARS-CoV-2 Seroprevalence, Oregon, USA, November 1, 2020-June 30, 2022",

abstract = "We estimated SARS-CoV-2 seroprevalence in children in Oregon, USA, at 6 time points. Seroprevalence increased linearly during November 2020-December 2021 and peaked in February 2022 at 38.8% (95% CI 32.8%-46.5%). We observed no increase in the seroprevalence trend after widespread school reopening. Seroprevalence estimates complement case-based cumulative incidence.",

author = "Falender, {Rebecca A.} and Mitchell, {Paul G.} and Guzman-Cottrill, {Judith A.} and Cieslak, {Paul R.} and Melissa Sutton",

year = "2023",

month = aug,

doi = "10.3201/eid2908.230471",

language = "English (US)",

volume = "29",

pages = "1672--1675",

journal = "Emerging infectious diseases",

issn = "1080-6040",

publisher = "Centers for Disease Control and Prevention (CDC)",

number = "8",

}

TY - JOUR

T1 - Pediatric SARS-CoV-2 Seroprevalence, Oregon, USA, November 1, 2020-June 30, 2022

AU - Falender, Rebecca A.

AU - Mitchell, Paul G.

AU - Guzman-Cottrill, Judith A.

AU - Cieslak, Paul R.

AU - Sutton, Melissa

PY - 2023/8

Y1 - 2023/8

N2 - We estimated SARS-CoV-2 seroprevalence in children in Oregon, USA, at 6 time points. Seroprevalence increased linearly during November 2020-December 2021 and peaked in February 2022 at 38.8% (95% CI 32.8%-46.5%). We observed no increase in the seroprevalence trend after widespread school reopening. Seroprevalence estimates complement case-based cumulative incidence.

AB - We estimated SARS-CoV-2 seroprevalence in children in Oregon, USA, at 6 time points. Seroprevalence increased linearly during November 2020-December 2021 and peaked in February 2022 at 38.8% (95% CI 32.8%-46.5%). We observed no increase in the seroprevalence trend after widespread school reopening. Seroprevalence estimates complement case-based cumulative incidence.

UR - http://www.scopus.com/inward/record.url?scp=85165563316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85165563316&partnerID=8YFLogxK

U2 - 10.3201/eid2908.230471

DO - 10.3201/eid2908.230471

M3 - Article

C2 - 37486347

AN - SCOPUS:85165563316

SN - 1080-6040

VL - 29

SP - 1672

EP - 1675

JO - Emerging infectious diseases

JF - Emerging infectious diseases

IS - 8

ER -

Pediatric SARS-CoV-2 Seroprevalence, Oregon, USA, November 1, 2020-June 30, 2022

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this